Satisfactory clinical response to erlotinib in a patient with Olmsted syndrome

About this course

• Released:
• Expires: February 6, 2035

Target Audience

This activity is intended for practicing dermatologists and other physicians involved in the treatment and management of diseases of the skin.

Learning Objective

To gain an understanding of TRPV3 mutation-associated Olmsted syndrome and the use of epidermal growth factor receptor inhibitors as an effective treatment for this disease, for which there is no curative treatment available.

Accreditation and Designation Statement

Once the test is passed, a certificate of completion will be generated. The learning activity can be added to the Royal College of Physicians' CPD diary as a self-certified entry.

Activity Disclosures

No commercial support has been accepted related to the development or publication of this activity.